Rotavirus vaccines: a story of success. 2015

H Kollaritsch, and M Kundi, and C Giaquinto, and M Paulke-Korinek
Institute of Specific Prophylaxis and Tropical Medicine, Medical University Vienna, Austria.

By January 2015, rotavirus vaccination had been implemented in national vaccination programmes in 75 countries worldwide. Two live oral rotavirus vaccines are internationally available: human, monovalent vaccine and human-bovine pentavalent reassortant vaccine. Since January 2014, another live, oral human-bovine monovalent vaccine has been available in India. After implementation of rotavirus vaccines in childhood immunization programmes, there has been an over 90% reduction of rotavirus hospitalizations in industrialized and resource-deprived countries. Additionally, in Latin America, significant reduction of rotavirus-associated deaths has been recorded. Still, numerous countries do not recommend rotavirus mass vaccination because of assumed lack of cost-effectiveness and potential risk of intussusception, which is estimated at 1 per 50 000-70 000 doses of rotavirus vaccines. Cost-effectiveness of vaccination is affected in some countries by high price. Inclusion of herd protection and indirect costs in calculations for cost-effectiveness results in clear benefit: costs saved by health systems due to reduced rotavirus gastroenteritis hospitalizations far exceed the costs for implementation of rotavirus vaccination. There have been objections that high rotavirus vaccination coverage could put selective pressure on certain rotavirus strains against which protection after vaccination is less distinct. However, data now strongly suggest that even if there might be a relative increase of some specific genotypes after the use of rotavirus vaccines, this is not an absolute increase in incidence from certain genotypes and does not affect the overall effectiveness of rotavirus mass vaccination, which resulted in a major decrease of severe cases of rotavirus gastroenteritis in both industrialized and resource deprived countries.

UI MeSH Term Description Entries
D007443 Intussusception A form of intestinal obstruction caused by the PROLAPSE of a part of the intestine into the adjoining intestinal lumen. There are four types: colic, involving segments of the LARGE INTESTINE; enteric, involving only the SMALL INTESTINE; ileocecal, in which the ILEOCECAL VALVE prolapses into the CECUM, drawing the ILEUM along with it; and ileocolic, in which the ileum prolapses through the ileocecal valve into the COLON. Invagination, Intestinal,Intususception,Intestinal Invagination,Intestinal Invaginations,Intussusceptions,Intususceptions,Invaginations, Intestinal
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012400 Rotavirus Infections Infection with any of the rotaviruses. Specific infections include human infantile diarrhea, neonatal calf diarrhea, and epidemic diarrhea of infant mice. Infection, Rotavirus,Infections, Rotavirus,Rotavirus Infection
D014943 Global Health A multi- and interdisciplinary field concerned with improving health and achieving equity in health for all people. It transcends national boundaries, promotes cooperation and collaboration within and beyond health science fields, and combines population-based disease prevention with individually-based patient care. International Health Problems,World Health,International Health,Worldwide Health,Health Problem, International,Health Problems, International,Health, Global,Health, International,Health, World,Health, Worldwide,Healths, International,International Health Problem,International Healths,Problem, International Health,Problems, International Health
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates
D017589 Immunization Programs Organized services to administer immunization procedures in the prevention of various diseases. The programs are made available over a wide range of sites: schools, hospitals, public health agencies, voluntary health agencies, etc. They are administered to an equally wide range of population groups or on various administrative levels: community, municipal, state, national, international. Vaccination Awareness,Vaccination Campaign,Vaccination Promotion,Awareness, Vaccination,Awarenesses, Vaccination,Campaign, Vaccination,Campaigns, Vaccination,Immunization Program,Program, Immunization,Programs, Immunization,Promotion, Vaccination,Promotions, Vaccination,Vaccination Awarenesses,Vaccination Campaigns,Vaccination Promotions
D022243 Rotavirus Vaccines Vaccines or candidate vaccines used to prevent infection with ROTAVIRUS. Rotavirus Vaccine,Vaccine, Rotavirus,Vaccines, Rotavirus

Related Publications

H Kollaritsch, and M Kundi, and C Giaquinto, and M Paulke-Korinek
January 2017, F1000Research,
H Kollaritsch, and M Kundi, and C Giaquinto, and M Paulke-Korinek
February 2018, Journal of tropical pediatrics,
H Kollaritsch, and M Kundi, and C Giaquinto, and M Paulke-Korinek
September 1994, Science (New York, N.Y.),
H Kollaritsch, and M Kundi, and C Giaquinto, and M Paulke-Korinek
October 2007, Medicine and health, Rhode Island,
H Kollaritsch, and M Kundi, and C Giaquinto, and M Paulke-Korinek
March 2009, The New England journal of medicine,
H Kollaritsch, and M Kundi, and C Giaquinto, and M Paulke-Korinek
January 2022, Journal of public health management and practice : JPHMP,
H Kollaritsch, and M Kundi, and C Giaquinto, and M Paulke-Korinek
January 2024, Lancet (London, England),
H Kollaritsch, and M Kundi, and C Giaquinto, and M Paulke-Korinek
October 2016, Nature nanotechnology,
H Kollaritsch, and M Kundi, and C Giaquinto, and M Paulke-Korinek
November 1991, Healthcare bottom line,
H Kollaritsch, and M Kundi, and C Giaquinto, and M Paulke-Korinek
May 1990, The Canadian nurse,
Copied contents to your clipboard!